Suppr超能文献

内皮细胞蛋白 C 受体拮抗组织因子驱动的间皮瘤生长。

Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor.

机构信息

Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, Texas 75708, USA.

出版信息

Cancer Res. 2013 Jul 1;73(13):3963-73. doi: 10.1158/0008-5472.CAN-12-1690. Epub 2013 Mar 28.

Abstract

The procoagulant protein tissue factor (F3) is a powerful growth promoter in many tumors, but its mechanism of action is not well understood. More generally, it is unknown whether hemostatic factors expressed on tumor cells influence tissue factor-mediated effects on cancer progression. In this study, we investigated the influence of tissue factor, endothelial cell protein C receptor (EPCR, PROCR), and protease activated receptor-1 (PAR1, F2R) on the growth of malignant pleural mesothelioma (MPM), using human MPM cells that lack or express tissue factor, EPCR or PAR1, and an orthotopic nude mouse model of MPM. Intrapleural administration of MPM cells expressing tissue factor and PAR1 but lacking EPCR and PAR2 (F2RL1) generated large tumors in the pleural cavity. Suppression of tissue factor or PAR1 expression in these cells markedly reduced tumor growth. In contrast, tissue factor overexpression in nonaggressive MPM cells that expressed EPCR and PAR1 with minimal levels of tissue factor did not increase their limited tumorigenicity. More importantly, ectopic expression of EPCR in aggressive MPM cells attenuated their growth potential, whereas EPCR silencing in nonaggressive MPM cells engineered to overexpress tissue factor increased their tumorigenicity. Immunohistochemical analyses revealed that EPCR expression in tumor cells reduced tumor cell proliferation and enhanced apoptosis. Overall, our results enlighten the mechanism by which tissue factor promotes tumor growth through PAR1, and they show how EPCR can attenuate the growth of tissue factor-expressing tumor cells.

摘要

促凝血蛋白组织因子(F3)是许多肿瘤中强有力的生长促进剂,但它的作用机制尚不清楚。更一般地说,尚不清楚肿瘤细胞上表达的止血因子是否会影响组织因子介导的对癌症进展的影响。在这项研究中,我们使用缺乏或表达组织因子、内皮细胞蛋白 C 受体(EPCR,PROCR)和蛋白酶激活受体-1(PAR1,F2R)的人恶性胸膜间皮瘤(MPM)细胞以及原位裸鼠 MPM 模型,研究了组织因子、内皮细胞蛋白 C 受体(EPCR,PROCR)和蛋白酶激活受体-1(PAR1,F2R)对恶性胸膜间皮瘤(MPM)生长的影响。在缺乏 EPCR 和 PAR2(F2RL1)的情况下表达组织因子和 PAR1 的 MPM 细胞的胸膜内给药会在胸膜腔内产生大肿瘤。这些细胞中组织因子或 PAR1 表达的抑制显着降低了肿瘤生长。相比之下,在非侵袭性 MPM 细胞中过表达组织因子,这些细胞表达 EPCR 和 PAR1,组织因子水平最低,不会增加其有限的致瘤性。更重要的是,在侵袭性 MPM 细胞中异位表达 EPCR 可减弱其生长潜能,而在非侵袭性 MPM 细胞中沉默 EPCR 可增强其过表达组织因子的致瘤性。免疫组织化学分析显示,肿瘤细胞中 EPCR 的表达降低了肿瘤细胞的增殖并增强了细胞凋亡。总体而言,我们的研究结果阐明了组织因子通过 PAR1 促进肿瘤生长的机制,并且表明 EPCR 如何减弱表达组织因子的肿瘤细胞的生长。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb93/3702650/c95ce81ef4d5/nihms-462879-f0001.jpg

相似文献

引用本文的文献

2
Rivaroxaban does not affect growth of human pancreatic tumors in mice.利伐沙班不会影响小鼠人胰腺肿瘤的生长。
J Thromb Haemost. 2019 Dec;17(12):2169-2173. doi: 10.1111/jth.14604. Epub 2019 Aug 26.
3
Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis.组织因子与癌症:调控、肿瘤生长和转移。
Semin Thromb Hemost. 2019 Jun;45(4):385-395. doi: 10.1055/s-0039-1687894. Epub 2019 May 16.
6
Endothelial cell protein C receptor-dependent signaling.内皮细胞蛋白 C 受体依赖性信号转导。
Curr Opin Hematol. 2018 May;25(3):219-226. doi: 10.1097/MOH.0000000000000416.
9
Drug development against the hippo pathway in mesothelioma.针对间皮瘤中河马通路的药物研发。
Transl Lung Cancer Res. 2017 Jun;6(3):335-342. doi: 10.21037/tlcr.2017.06.02.

本文引用的文献

9
Tissue factor in cancer progression and angiogenesis.组织因子在癌症进展和血管生成中的作用。
Thromb Res. 2010 Apr;125 Suppl 2(0 2):S36-8. doi: 10.1016/S0049-3848(10)70010-4.
10
Immunity, inflammation, and cancer.免疫、炎症与癌症。
Cell. 2010 Mar 19;140(6):883-99. doi: 10.1016/j.cell.2010.01.025.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验